CGTLive’s Weekly Rewind – December 2, 2022


Review top news and interview highlights from the week ending December 2, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CAR-T Outcome Measures Unaffected by Socioeconomic Status and Neighborhood Opportunity

There was no significant difference in OS and CR rate for patients based on household poverty and neighborhood opportunity.

2. Arshad Khanani, MD, on Reducing Treatment Burden in Wet AMD With Gene Therapy

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

3. GM1 Gangliosidosis Gene Therapy Trial Safe to Continue

Lysogene’s MPS IIIA gene therapy program recently failed its primary endpoint in the phase 2/3 AAVANCE trial.

4. Hemgenix Approval May Pave Way for Val-Rox in Hemophilia A

The FDA has decided not to hold an advisory committee meeting for Roctavian after all.

5. Maria Escolar, MD, on Addressing Unmet Needs in Krabbe Disease With Gene Therapy

The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.

Related Videos
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
David Porter, MD
Mitchell Horwitz, MD
Shalini Shenoy, MD, MBBS, the director of the Stem Cell Transplant & Cellular Therapy Program at St. Louis Children’s Hospital
N. Nora Bennani, MD
© 2024 MJH Life Sciences

All rights reserved.